BI 764532 was discovered using OBT’s proprietary OGAP® platform, the world's largest, cancer specific, membrane protein library used to identify novel, high specific antigens for cancer targets Oxford, UK, San Jose, Calif., 24th October 2023 - Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and antibody-drug conjugate (ADC)-based therapies, today announces that partner Boehringer Ingelheim dosed the first patient in a Phase 2 trial investigating BI 764532 (OBT620) for the treatment of small cell lung cancer (SCLC) and other neuroendocrine cancers.

BI 764532是使用OBT专有的OGAP®平台发现的，该平台是世界上最大的癌症特异性膜蛋白库，用于鉴定癌症靶标的新型高特异性抗原牛津，英国，加利福尼亚州圣何塞，2023年10月24日-牛津生物治疗学（OBT），一家临床阶段的肿瘤公司，拥有基于免疫肿瘤学和抗体-药物偶联物（ADC）的疗法，今天宣布合作伙伴勃林格殷格翰在第二阶段试验中为第一位患者服用BI 764532（OBT620）治疗小细胞肺癌（SCLC）和其他神经内分泌癌。

The Phase 2 study, ‘DAREON™-5’ (NCT05882058) is an open-label, multi-centre, dose-selection study evaluating two doses of BI 764532 in patients with relapsed/refractory extensive-stage SCLC and other relapsed/refractory neuroendocrine carcinomas. BI 764532 is an investigational T-Cell engager that might selectively redirect T cells (type of white blood cells called lymphocytes which help the immune system fight disease) towards the cancer cells expressing the DLL3 protein.

第二阶段研究，'DAREON™-5'（NCT05882058）是一项开放标签，多中心，剂量选择研究，评估两种剂量的BI 764532治疗复发/难治性广泛期SCLC和其他复发/难治性神经内分泌癌患者。BI 764532是一种研究性T细胞参与者，可以选择性地将T细胞（称为淋巴细胞的白细胞类型，帮助免疫系统抵抗疾病）重定向到表达DLL3蛋白的癌细胞。

DLL3 is minimally expressed in normal tissue but expressed in 80-85% of SCLC tumors, and approximately 77% of neuroendocrine carcinomas (NECs)1 making DLL3 an ideal therapeutic target for these two indications of high unmet medical need. Christian Rohlff, PhD, Chief Executive Officer of Oxford BioTherapeutics, said: “The start of this Phase 2 trial with BI 764532, the most advanced candidate with our partner Boehringer Ingelheim which was discovered using our proprietary OGAP® platform, is a major milestone for OBT.

DLL3在正常组织中最低限度表达，但在80-85%的SCLC肿瘤和大约77%的神经内分泌癌（NEC）1中表达，使得DLL3成为这两种高度未满足医疗需求指征的理想治疗靶标。牛津生物治疗公司首席执行官克里斯蒂安·罗尔夫（Christian Rohlff）博士说：“BI 764532是我们合作伙伴勃林格殷格翰（Boehringer Ingelheim）最先进的候选人，使用我们专有的OGAP®平台进行的第二阶段试验的开始，是一个重要的里程碑OBT。

The progression to Phase 2 development and recent US FDA fast track designation, validates the power of our platform and discovery capabilities to identify targets that kick start the develop.

进入第二阶段开发和最近的美国FDA快速通道指定，验证了我们的平台和发现能力的强大功能，以确定启动开发的目标。